Evidence map›Paper›PMID 21748597›Full record

ArticleProtein & cell2011

Hrs inhibits citron kinase-mediated HIV-1 budding via its FYVE domain.

Jiwei Ding, Lishan Su, Guangxia Gao

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Protein & cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Jiwei DingKey Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing.
Lishan Su
Guangxia Gao
Chinese Academy of Sciences · CNUniversity of Chinese Academy of Sciences · CNUniversity of North Carolina at Chapel Hill · US

Funding

RHOA EFFECTOR IN HIV-1 REPLICATION AND PATHOGENESISR01AI048407 · NIAID · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI SU, LISHAN · 2000 to 2004
$1.6M
Treg in HIV-1 Replication and PathogenesisR01AI077454 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SU, LISHAN · 2008 to 2011
$1.5M
NIAID NIH HHS R01 AI048407NIAID NIH HHS R01 AI077454
6 · The paper itself

Abstract

Hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) is a key component of the endosomal sorting complexes required for transport and has been demonstrated to play a regulatory role in endocytosis/exocytosis and the accumulation of internal vesicles in multivesicular bodies. Citron kinase is a Ser/The kinase that we previously reported to enhance human immunodeficiency virus type 1 (HIV-1) virion production. However, the relationship between Hrs and citron kinase in HIV-1 production remains elusive. Here, we report that Hrs interacts with citron kinase via its FYVE domain. Overexpression of Hrs or the FYVE domain resulted in a significant decrease in HIV-1 virion production. Depletion of Hrs by RNA interference in HEK293T cells increased HIV-1 virion production and enhanced the activity of citron kinase. These data suggest that Hrs inhibits HIV-1 production by inhibiting citron kinase-mediated exocytosis.

Indexed as

Endosomal Sorting Complexes Required for TransportHIV-1Intracellular Signaling Peptides and ProteinsPhosphoproteinsProtein Serine-Threonine KinasesDown-RegulationEndosomesExocytosisGene ExpressionGene SilencingHEK293 CellsHIV InfectionsHumansImmunoprecipitationMicroscopy, FluorescencePlasmidscitron-kinaseEndosomal Sorting Complexes Required for Transporthepatocyte growth factor-regulated tyrosine kinase substrateIntracellular Signaling Peptides and ProteinsPhosphoproteinsProtein Serine-Threonine KinasesRNA, Small Interfering

Identifiers

PMID21748597
PMCPMC4420243
OpenAlexW2159991606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.